Observational Study of Kibow Biotics in Chronic Kidney Failure Patients on Dialysis
Launched by KIBOW PHARMA · Oct 10, 2011
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
Probiotics are increasingly utilized clinically. As their safety and health benefits are established, it is reasonable to anticipate that probiotic bacteria will be incorporated into a growing number of clinical regimens, as a dietary supplement.
Extensive in vitro R\&D investigations in Kibow's laboratories
Bacterial strains studied were a mixture of patented and proprietary strains of Streptococcus thermophilus (KB27), Lactobacillus acidophilus (KB31) and Bifidobacterium longum (KB35).
Oral administration of these bacterial formulations, tested in the 5/6th nephrectomized rat model (at...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Currently on hemodialysis
- • 18 to 75 years of age
- • Willing to give informed consent
- • Baseline serum creatinine \>2.5 mg/dL
- Exclusion Criteria:
- • Pregnant or nursing women
- • Refusal to sign the informed consent form
- • Documented to have HIV/AIDS/Liver disease
- • Active dependency on drugs or alcohol
- • Currently on anticoagulant therapy
About Kibow Pharma
Kibow Pharma is a biotechnology company dedicated to advancing innovative therapeutic solutions for chronic kidney disease and related conditions. With a focus on developing proprietary probiotic formulations, Kibow Pharma aims to enhance renal health and improve the quality of life for patients through evidence-based clinical research. The company is committed to scientific rigor and patient-centered approaches, leveraging its expertise in microbiome research to address unmet medical needs in the field of nephrology. Through strategic collaborations and clinical trials, Kibow Pharma seeks to establish itself as a leader in the development of novel therapies that promote kidney function and overall well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brooklyn, New York, United States
Patients applied
Trial Officials
Subodh J Saggi, M.D., MPH
Principal Investigator
Downstate Medical Center
Mary Mallapallil, M.D.
Principal Investigator
Kings County Medical Center
Eli Friedman, M.D., MACP, FRCP
Principal Investigator
Downstate Medical Center
Gary Briefel, M.D.
Principal Investigator
Kings County Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials